Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02109627
Title Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors C. Babis Andreadis

acute myeloid leukemia


Cytarabine + Ficlatuzumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.